{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:57:15Z","timestamp":1792645035377,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s41030-026-00366-x","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:05:59Z","timestamp":1780394759000},"page":"667-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes across Baseline Risk Profiles in Patients with COPD Initiating Budesonide\/Glycopyrronium\/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct06321731","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-9366","authenticated-orcid":false,"given":"Bernardino","family":"Alc\u00e1zar-Navarrete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1564-1172","authenticated-orcid":false,"given":"Juan Marco","family":"Figueira-Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-0558","authenticated-orcid":false,"given":"Nagore","family":"Blanco Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-0237","authenticated-orcid":false,"given":"Nuria","family":"Bruguera Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-2316","authenticated-orcid":false,"given":"Roberto","family":"Bernabeu Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2642-4453","authenticated-orcid":false,"given":"Antonia","family":"Fuster Gomila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3703-1869","authenticated-orcid":false,"given":"Ra\u00fal","family":"Galera Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0463-5946","authenticated-orcid":false,"given":"Marta M.","family":"Garc\u00eda Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1902-1835","authenticated-orcid":false,"given":"Galo","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0284-3840","authenticated-orcid":false,"given":"Hassan","family":"Khadour Khadour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5715-7613","authenticated-orcid":false,"given":"Eduardo","family":"M\u00e1rquez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5561-4517","authenticated-orcid":false,"given":"Igor","family":"Murga Arizabaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3932-8674","authenticated-orcid":false,"given":"Jose Luis","family":"Velasco Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0260-360X","authenticated-orcid":false,"given":"Carmen","family":"Corregidor-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-5249","authenticated-orcid":false,"given":"Eunice","family":"Fitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-3669","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"S\u00e1nchez-Covisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"366_CR1","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1007\/s12325-025-03361-x","volume":"42","author":"B Alc\u00e1zar-Navarrete","year":"2025","unstructured":"Alc\u00e1zar-Navarrete B, Figueira-Gon\u00e7alves JM, Corregidor-Garc\u00eda C, Fitas E, S\u00e1nchez-Covisa J, M\u00e1rquez-Mart\u00edn E, et\u00a0al. Real-world outcomes in patients with COPD initiating budesonide\/glycopyrronium\/formoterol fumarate dehydrate in Spain: ORESTES study. Adv Ther. 2025;42:5708\u201326.","journal-title":"Adv Ther"},{"key":"366_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-026-00341-6","author":"JM Figueira-Gon\u00e7alves","year":"2026","unstructured":"Figueira-Gon\u00e7alves JM, Alc\u00e1zar-Navarrete B, Casitas-Mateo R, Gonz\u00e1lez J, Gotera-Rivera CM, Herrej\u00f3n-Silvestre A, et\u00a0al. Real-world outcomes in patients with COPD initiating budesonide\/glycopyrronium\/formoterol fumarate dihydrate after dual and triple therapy in Spain: a sub-study of the ORESTES study. Pulm Ther. 2026. https:\/\/doi.org\/10.1007\/s41030-026-00341-6.","journal-title":"Pulm Ther"},{"issue":"11","key":"366_CR3","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","volume":"206","author":"B Celli","year":"2022","unstructured":"Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, et\u00a0al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med. 2022;206(11):1317\u201325.","journal-title":"Am J Respir Crit Care Med"},{"key":"366_CR4","unstructured":"Chronic obstructive pulmonary disease (COPD). World Health Organization: World Health Organization; 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd)."},{"issue":"10342","key":"366_CR5","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","volume":"399","author":"SA Christenson","year":"2022","unstructured":"Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227\u201342.","journal-title":"Lancet"},{"key":"366_CR6","unstructured":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2026 report). Global initiative for chronic obstructive lung disease. 2026. https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/. Accessed Feb 2026."},{"issue":"1","key":"366_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12931-024-03051-2","volume":"26","author":"Z Wang","year":"2025","unstructured":"Wang Z, Lin J, Liang L, Huang F, Yao X, Peng K, et\u00a0al. Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021. Respir Res. 2025;26(1):2.","journal-title":"Respir Res"},{"key":"366_CR8","unstructured":"Trixeo aerosphere: summary of product characteristics. European Medicines Agency. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trixeo-aerosphere-epar-product-information_en.pdf."},{"issue":"12","key":"366_CR9","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.arbres.2025.10.008","volume":"61","author":"M Miravitlles","year":"2025","unstructured":"Miravitlles M, Calle M, Molina J, Almagro P, G\u00f3mez JT, Trigueros JA, et\u00a0al. Update 2025 of the Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol. 2025;61(12):766\u201382.","journal-title":"Arch Bronconeumol"},{"issue":"10","key":"366_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et\u00a0al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"366_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et\u00a0al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"366_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","volume":"203","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et\u00a0al. Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"366_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106509","volume":"185","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Trivedi R, Jenkins M, et\u00a0al. Benefits of budesonide\/glycopyrrolate\/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021;185:106509.","journal-title":"Respir Med"},{"key":"366_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/17534666211034329","volume":"15","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Martinez FJ, Singh D, Trivedi R, Jenkins M, Darken P, et\u00a0al. Improvements in lung function with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. Ther Adv Respir Dis. 2021;15:17534666211034329.","journal-title":"Ther Adv Respir Dis"},{"key":"366_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2025.02.004","author":"A Hammadi","year":"2025","unstructured":"Hammadi A, Hoyas-S\u00e1nchez C, Romero-Linares A, \u00c1lvarez-Muro L, Men\u00e9ndez-Lobo A, Romeral-Navarro D, et\u00a0al. All-cause and cardiovascular mortality with single inhaler triple therapy versus double therapies for COPD: a systematic review and metanalysis. Arch Bronconeumol. 2025. https:\/\/doi.org\/10.1016\/j.arbres.2025.02.004.","journal-title":"Arch Bronconeumol"},{"key":"366_CR16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/COPD.S452624","volume":"19","author":"H M\u00fcllerov\u00e1","year":"2024","unstructured":"M\u00fcllerov\u00e1 H, Chan JSK, Heatley H, Carter V, Townend J, Skinner D, et\u00a0al. Budesonide\/glycopyrrolate\/formoterol for the management of COPD in a UK primary care population: real-world use and early medication success. Int J Chron Obstruct Pulmon Dis. 2024;19:1153\u201366.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"366_CR17","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2147\/COPD.S432963","volume":"18","author":"C Strange","year":"2023","unstructured":"Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, et\u00a0al. Exacerbations and real-world outcomes after single-inhaler triple therapy of budesonide\/glycopyrrolate\/formoterol fumarate, among patients with COPD: results from the EROS (US) study. Int J Chron Obstruct Pulmon Dis. 2023;18:2245\u201356.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"suppl 68","key":"366_CR18","first-page":"PA2999","volume":"64","author":"Y Sun","year":"2024","unstructured":"Sun Y, Chen Y, Zhang X, Guo R, Zhou L, Feng J, et\u00a0al. Real-world safety of budesonide\/glycopyrrolate\/formoterol in Chinese patients with chronic obstructive pulmonary disease. Eur Respir J. 2024;64(suppl 68):PA2999.","journal-title":"Eur Respir J"},{"issue":"4","key":"366_CR19","doi-asserted-by":"publisher","first-page":"A4716","DOI":"10.1016\/j.chest.2024.06.2841","volume":"166","author":"Y Sun","year":"2024","unstructured":"Sun Y, Chen Y, Zhang X, Guo R, Zhou L, Feng J, et\u00a0al. Effectiveness of budesonide\/glycopyrrolate\/formoterol fumarate in Chinese patients with chronic obstructive pulmonary disease in real-world clinical practice. Chest. 2024;166(4):A4716\u20137.","journal-title":"Chest"},{"issue":"4","key":"366_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semerg.2024.102418","volume":"51","author":"A Calder\u00f3n-Montero","year":"2025","unstructured":"Calder\u00f3n-Montero A, de Miguel DJ, de Sim\u00f3n GR, Campos T\u00e9llez S, Chac\u00f3n Moreno AD, Alonso Avil\u00e9s R, et\u00a0al. Triple inhaled therapy of formoterol\/glycopyrrolate\/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions. SEMERGEN. 2025;51(4):102418.","journal-title":"SEMERGEN"},{"key":"366_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112681","author":"B Sposato","year":"2025","unstructured":"Sposato B, Lacerenza LG, Croce S, Petrucci E, Fabbrini V, Giannini L, et\u00a0al. Real-life efficacy of single-inhaler triple therapy with budesonide\/glycopyrronium\/formoterol fumarate in persistent COPD users: a retrospective database study. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13112681.","journal-title":"Biomedicines"},{"issue":"5","key":"366_CR22","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.resinv.2025.05.007","volume":"63","author":"S Muro","year":"2025","unstructured":"Muro S, Hozawa S, Sugiura H, Yoshida Y, Makita N, Kato Y, et\u00a0al. Real-world effectiveness of budesonide\/glycopyrronium\/formoterol fumarate metered dose inhaler on symptoms and quality of life in patients with COPD: EBISU study. Respir Investig. 2025;63(5):726\u201333.","journal-title":"Respir Investig"},{"issue":"69 suppl","key":"366_CR23","first-page":"PA5697","volume":"66","author":"H Watz","year":"2024","unstructured":"Watz H, Halbach M, Saathoff M, Morris T, Watt M, FernandezMilano A, et\u00a0al. Real-world outcomes of budesonide\/glycopyrronium\/formoterol therapy in COPD after 12 months; the RECORD study. Eur Respir J. 2024;66(69 suppl):PA5697.","journal-title":"Eur Respir J"},{"key":"366_CR24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02240-2023","author":"DMG Halpin","year":"2024","unstructured":"Halpin DMG, Healey H, Skinner D, Carter V, Pullen R, Price D. Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations. Eur Respir J. 2024. https:\/\/doi.org\/10.1183\/13993003.02240-2023.","journal-title":"Eur Respir J"},{"key":"366_CR25","unstructured":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report). Global initiative for chronic obstructive lung disease. 2025. https:\/\/goldcopd.org\/2025-gold-report\/. Accessed Feb 2026."},{"key":"366_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030707","author":"M Calle Rubio","year":"2025","unstructured":"Calle Rubio M, Catalu\u00f1a JJS, Miravitlles M, Navarrete BA, L\u00f3pez-Campos JL, Ferrer MEF, et\u00a0al. Development and validation of a quantitative score for the criteria clinical control in stable COPD proposed in the Spanish COPD guidelines (GesEPOC): results of the EPOCONSUL audit. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14030707.","journal-title":"J Clin Med"},{"issue":"12","key":"366_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006171","volume":"4","author":"H M\u00fcllerov\u00e1","year":"2014","unstructured":"M\u00fcllerov\u00e1 H, Shukla A, Hawkins A, Quint J. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4(12):e006171.","journal-title":"BMJ Open"},{"issue":"7","key":"366_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0327775","volume":"20","author":"M Calle Rubio","year":"2025","unstructured":"Calle Rubio M, Alc\u00e1zar-Navarrete B, L\u00f3pez-Campos JL, Miravitlles M, Soler-Catalu\u00f1a JJ, Fuentes Ferrer ME, et\u00a0al. Characteristics and actions in high-risk COPD in unstable patients: the EPOCONSUL audit. PLoS ONE. 2025;20(7):e0327775.","journal-title":"PLoS ONE"},{"issue":"1","key":"366_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.arbres.2025.06.003","volume":"62","author":"JJ Soler-Catalu\u00f1a","year":"2026","unstructured":"Soler-Catalu\u00f1a JJ, Villagrasa M, Catal\u00e1n P, Alc\u00e1zar-Navarrete B, Calle Rubio M, Miravitlles M. Risk validation of a new quantitative score for clinical control of chronic obstructive pulmonary disease: the RADAR score. Arch Bronconeumol. 2026;62(1):28\u201334.","journal-title":"Arch Bronconeumol"},{"issue":"9","key":"366_CR30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","volume":"7","author":"S Pascoe","year":"2019","unstructured":"Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et\u00a0al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745\u201356.","journal-title":"Lancet Respir Med"},{"key":"366_CR31","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.2147\/COPD.S374670","volume":"17","author":"M Bafadhel","year":"2022","unstructured":"Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, et\u00a0al. Benefits of budesonide\/glycopyrronium\/formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: a post-hoc analysis of data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022;17:3061\u201373.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"366_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/thorax-2022-219320","volume":"79","author":"H Whittaker","year":"2024","unstructured":"Whittaker H, Rothnie KJ, Quint JK. Cause-specific mortality in COPD subpopulations: a cohort study of 339 647 people in England. Thorax. 2024;79(3):202\u20138.","journal-title":"Thorax"},{"key":"366_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1525709","volume":"12","author":"WH Hsu","year":"2025","unstructured":"Hsu WH, Shiau BW, Lai CC, Liao KM. Association between eosinophil count and prognosis in chronic obstructive pulmonary disease patients. Front Med (Lausanne). 2025;12:1525709.","journal-title":"Front Med (Lausanne)"},{"key":"366_CR34","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.2147\/COPD.S431829","volume":"18","author":"M Tur\u00e9gano-Yedro","year":"2023","unstructured":"Tur\u00e9gano-Yedro M, Trillo-Calvo E, Navarro IRF, Maya-Viejo JD, Gonz\u00e1lez Villaescusa C, Echave Sustaeta JM, et\u00a0al. Inhaler adherence in COPD: a crucial step towards the correct treatment. Int J Chron Obstruct Pulmon Dis. 2023;18:2887\u201393.","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00366-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:24:50Z","timestamp":1782141890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00366-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00366-x","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bernardino Alc\u00e1zar-Navarrete declares conflicts of interest for having received consulting fees, research grants, or lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK, Laboratorios Bial, Laboratorios Menarini, and Sanofi. Bernardino Alc\u00e1zar-Navarrete is an editorial board member of\n                      Pulmonary Therapy\n                      . Bernardino Alc\u00e1zar-Navarrete was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Juan Marco Figueira-Gon\u00e7alves has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, Laboratories Esteve, MundiPharma, Boehringer Ingelheim, Ferrer, Menarini, Rovi, GSK, Chiesi, Novartis, and Gebro Pharma. Nagore Blanco Cid has received report grants for speaking at sponsored meetings from AstraZeneca, Gebro, Menarini, Sanofi, and Zambon. Nuria Bruguera Avila has received speaker fees from AstraZeneca, Menarini, CSL-Bering, Grifols, Bial, Gebro, Chiesi, Zambon, and GlaxoSmithKline. Roberto Bernabeu Mora declares payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from AstraZeneca, GSK, FAES, Zambon, and Chiesi. Antonia Fuster Gomila declares payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from AstraZeneca, Chiesi, GSK, FAES, and Menarini. Ra\u00fal Galera Mart\u00ednez declares conflicts of interest for having received consulting fees from Chiesi, Sanofi, Bial, and AstraZeneca, and funding for conference attendance from Bial, Sanofi, and FAES Farma. Marta M. Garc\u00eda Clemente has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, GSK, Chiesi, Sanofi, and Menarini. Galo Granados has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Zambon, and GlaxoSmithKline. Hassan Khadour Khadour declares that he has no conflicts of interest. Eduardo M\u00e1rquez-Mart\u00edn declares payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from AstraZeneca, Bial, Chiesi, GlaxoSmithKline, MSD, Pulmonx, and Sanofi\/Regeneron. Igor Murga Arizabaleta declares conflicts of interest for having received consulting fees, research grants, or lectures from AstraZeneca, CSL Behring, FAES, Grifols, GSK, Laboratorios Bial, and Sanofi. Jose Luis Velasco Garrido has received consulting fees from AstraZeneca and Sanofi, and honoraria for speaking engagements from Sanofi, AstraZeneca, and GSK. Carmen Corregidor-Garc\u00eda, Eunice Fitas, and Joaqu\u00edn S\u00e1nchez-Covisa are employees of AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The ORESTES study was approved by the Ethics Committee of Complejo Hospitalario Universitario de Canarias (Santa Cruz de Tenerife, Spain) on 25 May 2024 (minutes no. 05\/2024, regular virtual meeting). This study adhered to ethical principles consistent with the Declaration of Helsinki (1964 and its later amendments), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice, and the applicable legislation on noninterventional studies and\/or observational studies. The Ethics Committee waived the requirement for written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors thank all the individuals who participated in the study and acknowledge the contribution of the patients whose retrospectively collected data made this study possible.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Thanking Patient Participants"}}]}}